Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up.

Adding oral clodronate to postoperative adjuvant breast cancer therapy significantly improves disease-free survival (DFS) and overall survival (OS). Long-term follow-up data from the prospective, randomized, controlled study are reported.
Patients with primary breast cancer received clodronate 1600 mg/day for 2 years or no treatment along with standard adjuvant breast cancer treatment.
Analysis of 290 of 302 patients demonstrated that a significant improvement in OS was maintained in the clodronate group at a median follow-up of 103 +/- 12 months; 20.4% of patients in the clodronate group versus 40.7% of control group patients (P = 0.04) died during the 8.5 years following primary surgical therapy. Significant reductions in the incidence of bony and visceral metastases and improvement in duration of DFS at 36- and 55-month follow-up periods were no longer seen with clodronate.
These long-term survival data extend the survival advantage reported in previous studies with oral clodronate in breast cancer.
AuthorsI J Diel, A Jaschke, E F Solomayer, C Gollan, G Bastert, C Sohn, F Schuetz
JournalAnnals of oncology : official journal of the European Society for Medical Oncology / ESMO (Ann Oncol) Vol. 19 Issue 12 Pg. 2007-11 (Dec 2008) ISSN: 1569-8041 [Electronic] England
PMID18664560 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Bone Density Conservation Agents
  • Clodronic Acid
  • Administration, Oral
  • Adult
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Bone Density Conservation Agents (administration & dosage)
  • Bone Marrow (pathology)
  • Bone Neoplasms (epidemiology, prevention & control)
  • Breast Neoplasms (mortality, pathology, therapy)
  • Chemotherapy, Adjuvant (methods)
  • Clodronic Acid (administration & dosage)
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Kaplan-Meier Estimate
  • Mastectomy
  • Middle Aged
  • Radiotherapy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: